Niagen Bioscience

Niagen Bioscience Inc is a publicly traded bioscience company headquartered in Los Angeles, California, trading on NASDAQ under the ticker symbol NAGE. Founded in 1999 as ChromaDex Corporation, the company officially changed its name to Niagen Bioscience in March 2025, reflecting its focus as the global leader in nicotinamide adenine dinucleotide N... AD+ research and technology. The company operates through three business segments including consumer products, ingredients, and analytical reference standards and services. Niagen Bioscience specializes in developing, manufacturing, and commercializing proprietary ingredient technologies centered around Niagen, its patented nicotinamide riboside chloride, which serves as an NAD+ precursor clinically proven to increase NAD+ levels by up to 150 percent. The company's product portfolio includes Tru Niagen, a premium food-grade oral supplement for daily cellular vitality sold directly to consumers through its proprietary e-commerce platform, Amazon, specialty retailers, and healthcare practitioners, as well as Niagen Plus, a pharmaceutical-grade line of fast-acting NAD+ enhancement therapies including IV and injectable formulations available exclusively through healthcare providers. Niagen Bioscience operates ISO/IEC 17025:2017 accredited laboratories and maintains a robust intellectual property portfolio protected by over 50 global patents. The company's ChromaDex External Research Program provides NAD+ precursor research materials to academic and government research communities, with over 40 percent of all nicotinamide riboside peer-reviewed publications worldwide using its material. Niagen Bioscience has established partnerships with leading research institutions including the National Institutes of Health, the Biotechnology and Biological Sciences Research Council, and Northwestern University Feinberg School of Medicine, and collaborates with world-renowned scientists including Nobel laureates to advance NAD+ science. The company's Niagen ingredient has received ...Read More